Announcements Trials
Browse Landscape

Phase

Phase 2 14Phase 3 10Phase 4 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Dermatologic 1

Conditions

Facies 1Carcinoma, Basal Cell 1

Interventions

Imiquimod 15Aminolevulinic Acid 8Fluorouracil 6Diclofenac 63-ingenyl angelate 6Nivolumab 5Cryotherapy 5tirbanibulin 4methyl 5-aminolevulinate 4Sirolimus 4denileukin diftitox 3aldesleukin 3Photochemotherapy 3Ipilimumab 3Blood Specimen Collection 3relatlimab 2Vemurafenib 2Tacrolimus 2Prednisone 2Ointments 2Methotrexate 2Immune Checkpoint Inhibitors 2HhAntag691 2Gels 2Cyclosporine 2Cryosurgery 2trametinib 1technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1technetium Tc 99m nanocolloid 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Interferon-alpha × Dermatologic × Clear all
NCT00581425 2013-01-25

Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)

The University of Texas Health Science Center, Houston

Phase 4 Completed
49 enrolled
Dermatologic

Carcinoma, Basal Cell, Facies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡